US expansion for pharmaceutical and biotech firm
A Cheshire-based pharmaceutical and biotech product development consultancy has launched a US operation
Boyds has opened an office in Philadelphia, Pennsylvania’s largest city, which is an ideal location for many of group’ East Coast clients and provides a link between different time zones from Europe to the West Coast.
As part of the expansion, Boyd has also recruited Katy Rudnick as vice president and head of US Regulatory Affairs to lead the US business.
Since Boyds was established in 2005, the company has worked with US companies seeking to develop and gain approval for their medicines in Europe and further afield.
Over recent years the consultancy has experienced a steady increase in the number of companies approaching Boyds for its expertise, with more than 60% of the company’s client base now in the US.
President and founder of Boyds, Professor Alan Boyd, said: “The US is the largest biotech market globally, and we have a strong and growing client base in the US.
“Opening the office in Pennsylvania is the natural next step for Boyds and having a presence on the ground will ensure we can work closely with US clients looking to develop and take their products forward for approval with regulators in the US, but also the UK and Europe, via our UK and Dublin offices.”
Katy Rudnick will brings 20 years of regulatory and quality experience in the US, having worked across all therapeutic areas and dosage forms.
Prior to joining Boyds, Katy was director of Regulatory Affairs at Lupin Pharmaceuticals where she was responsible for a product portfolio of around 400 products at various stages.
Katy has also held regulatory roles at Lannett Company, Teva Pharmaceuticals and Mars Fishcare North America.
Prof Boyd said: “I am also delighted to welcome Katy to lead our US Regulatory Affairs activities and run the US office. She brings a strong scientific background and a wealth of regulatory experience including established links with the FDA and her wide network.
“We plan to grow the team further to extend our service offerings across programme management, medical monitoring, clinical operations and consultancy directly from within the US, expanding and adding to our UK and Ireland-based teams.”
Katy added: “It is an honour to work alongside them and I am excited to be creating the US office and building on the reputation of Boyds across the US, particularly in cutting-edge advanced therapies.”
